Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | TPO | P07202 | 1/20 | 0.36 |
| ▸ | EPX | P11678 | 1/20 | 0.36 |
| ▸ | LPO | P22079 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038355 | 0.82 | MCHR1 (0.38) | MCHR1TOP1TSHRCHEK1CHEK2 | |
| SCHEMBL13075015 | 0.81 | MCHR1 (0.45) | MCHR1MPOTPOEPXLPO | |
| SCHEMBL18291198 | 0.81 | MCHR1 (0.38) | MCHR1TOP1TSHRCHEK1CHEK2 | |
| SCHEMBL20038354 | 0.81 | MCHR1 (0.40) | MCHR1TOP1TSHRCHEK1CHEK2 | |
| SCHEMBL1000603 | 0.79 | NOS3 (0.46) | MCHR1MPOTPOEPXLPO | |
| SCHEMBL20249448 | 0.78 | CHEK1 (0.37) | MCHR1TOP1TSHRCHEK1CHEK2 | |
| SCHEMBL8511953 | 0.78 | TDP1 (0.47) | MCHR1TOP1TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL710140 | 0.77 | NOS3 (0.45) | MCHR1MPOTPOEPXLPO | |
| SCHEMBL25399464 | 0.76 | MPO (0.36) | MCHR1MPOTPOEPXLPO | |
| SCHEMBL25399467 | 0.76 | MPO (0.36) | MCHR1MPOTPOEPXLPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016194831-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | MCHR1 4511/4885TOP1 1172/4885MPO 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.